AMP01
/ Reverb Therapeutics
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 18, 2026
Quantitative Systems Pharmacology (QSP) enables research and translation of AMP01, a novel next generation anti PD1 bispecific that amplifies and redirects endogenous IL15 to PD1 high expressing T Cells, maximizing efficacy and therapeutic index
(AACR 2026)
- "Abstract is embargoed at this time."
Bispecific • Clinical • Late-breaking abstract • Oncology • IL15
1 to 1
Of
1
Go to page
1